A significant peptide update in 2026 has set in motion a significant regulatory shift for some of the most widely researched compounds in the peptide space. Following an announcement by Robert F. Kennedy Jr., United States Secretary of Health and Human Services, 12 peptides previously classified under FDA Category 2 will be removed from that
There is no shortage of information about starting a peptide cycle. Protocols, dosing schedules, and expected benefits are well documented. What receives far less attention is the other end of the process. Stopping Peptide Therapy is a biological event in its own right, and for a meaningful proportion of people, the transition off a cycle
In a February 27, 2026 appearance on the Joe Rogan Experience podcast, Health and Human Services Secretary Robert F. Kennedy Jr. articulated intentions to pursue reclassification of approximately 14 peptides from FDA Category 2 status back to Category 1, a policy reversal that, if implemented, would restore legal compounding access to compounds prohibited since September
Peptide therapy is a rapidly growing field in medicine, offering a promising solution for various health conditions. As this treatment gains momentum, the need for a comprehensive guide on how to safely inject peptides has become increasingly crucial. If you’re new to the world of peptide therapy, this beginner’s guide will provide you with the
Dr. Vladimir Khavinson, a renowned Russian gerontologist and professor, has revolutionized the field of peptide therapies. His groundbreaking work in bioregulation and longevity has earned him global recognition. As a member of the Russian Academy of Sciences and the Russian Academy of Medical Sciences, Khavinson has made significant contributions to our understanding of the activity
